VR17-04

VR17-04, the active metabolite of Enisamium, acts as a nucleoside analog inhibitor of viral RNA synthesis by blocking GTP and UTP incorporation, as demonstrated by computational studies. This mechanism supports its investigation as a potential broad-spectrum antiviral agent in both in vitro and animal model studies for COVID-19 and other RNA virus infections.